echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Biopharmaceuticals Valsartan Hydrochlorothiazide Tablets Approved for Listing! The first company to pass the consistency evaluation

    Biopharmaceuticals Valsartan Hydrochlorothiazide Tablets Approved for Listing! The first company to pass the consistency evaluation

    • Last Update: 2020-02-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On February 13, the Valsartan hydrochlorothiazide tablets (cyhs1800102) declared by Baiao Pharmaceutical Co., Ltd according to the new four categories were approved by the State Food and Drug Administration for listing, which was deemed to have passed the consistency evaluation, and the State Food and drug administration has arranged to issue the drug approval documents This is another large-scale antihypertensive drug obtained by Baiao pharmaceutical industry after the approval of valsartan amlodipine tablets, the first imitation of valsartan tablets, on February 5 Co Diovan, the original drug of valsartan hydrochlorothiazide tablets, was developed by Novartis It is a single compound antihypertensive drug composed of valsartan and hydrochlorothiazide, an angiotension receptor antagonist (ARB) It is mainly used for the treatment of mild to moderate essential hypertension, which can not be fully controlled by a single drug It was first listed in 1998 Before that, six domestic enterprises had been listed to sell valsartan hydrochlorothiazide tablets, and Baiao pharmaceutical industry became the first enterprise that passed the consistency evaluation of the product Source: after pharmago, only CR Secco has submitted the supplementary application of "consistency evaluation" in November 2019 Other related listed enterprises have completed the be test, but no application for consistency evaluation has been submitted Application for conformity evaluation of valsartan hydrochlorothiazide tablets completion of be test of valsartan hydrochlorothiazide tablets source: pharmago For patients with hypertension, compared with single mechanism antihypertensive drugs or free combination of different mechanism antihypertensive drugs, single compound drugs not only have obvious advantages in antihypertensive efficacy, prevention of cardiovascular and cerebrovascular complications, and reduction of adverse reactions, but also can effectively reduce the proportion of drug missed and improve compliance In recent years, European, American, Japanese and other countries have successively updated hypertension management guidelines to recommend single-chip compound antihypertensive preparations more and more At present, the domestic commonly used single-chip compound antihypertensive drugs include valsartan hydrochlorothiazide tablets, valsartan amlodipine tablets (I), irbesartan hydrochlorothiazide tablets, losartan hydrochlorothiazide, etc Novartis' valsartan hydrochlorothiazide tablets and valsartan amlodipine tablets are the basic drugs for clinical hypotensive treatment, with a wide range of applications Even after the patent period expires in 2019, they still have a total sales revenue of about 2.1 billion US dollars Source: pharmago is the magic prescription of medicine in the domestic market Valsartan amlodipine tablet is the only single-chip compound antihypertensive drug that has entered the national basic drug catalog It has a broad drug base in the grassroots market, with a domestic market scale of about 1 billion yuan According to IPM data, the domestic market size of valsartan hydrochlorothiazide tablets is about 450 million yuan, and more than 60% of the market share belongs to Novartis Baiao Pharmaceutical Co., Ltd has been in the forefront of domestic enterprises in the consistency evaluation of valsartan amlodipine tablets and valsartan hydrochlorothiazide tablets, which are two classic compound antihypertensive drugs It will also take the lead in breaking the monopoly of the original research drug market and bringing more drug choices to domestic patients.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.